Identification of HLA haplotype in tumor cells, after relapse following allogeneic hematopoietic stem cell transplantation from a haploidentical donor for hematological malignancy

Identification of HLA haplotype in tumor cells, after relapse following allogeneic hematopoietic stem cell transplantation from a haploidentical donor for hematological malignancy - Identification of HLA haplotype in relapsed tumor cells after haploidentical transplantation

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029097

Enrollment

Registered

2017-09-12

Start date

2017-08-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relpased hematological malignancy after haploidnetical HSCT

Interventions

The identification of HLA haplotype in relapsed tumor cells after haploidentical HSCT.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Relapsed patients after haploidentical HSCT for hematological malignancy.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
the rate of the loss of mismatched haplotype in tumor cells after relapse	—

Countries

Japan

Contacts

Public ContactShinichi Kako

Saitama Medical Center, Jichi Medical University Division of Hematology

shinichikako@asahi-net.email.ne.jp+81-48-647-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026